Press Releases

Find the latest news on AGC Biologics partnerships, product approvals, site expansions, leadership updates, new programs, and more.

Mammalian & mAbs (2)

AGC Biologics recognized as a Børsen Gazelle company of 2022

1 min read

AGC Biologics Copenhagen named Børsen Gazelle company for 2022

February 9, 2023 at 12:00 AM

Read press release

AGC Biologics and Provention Bio partner together.

2 min read

AGC Biologics Commercially Manufacture Provention Bio Diabetes Therapy

January 24, 2023 at 5:50 AM

Mammalian & mAbs Press Release Business Updates

Read press release

2 min read

AGC Biologics and Gore Collaborate on New Protein A-based Purification Technology and Contract Manufacturing Services for Antibody Therapies

December 12, 2022 at 8:32 AM

Mammalian & mAbs Press Release Business Updates

Read press release

AGC Biologics, winner of 2022 Global Excellence Award.

1 min read

AGC Biologics Honored for Innovations in Cell Line Development

October 13, 2022 at 7:46 AM

Mammalian & mAbs Press Release Business Updates Cell Line Development

Read press release

AGC Biologics honored by American Business Awards

1 min read

AGC Biologics Named Manufacturing Company of the Year by American Business Awards

June 29, 2022 at 6:00 AM

Cell & Gene Therapy Mammalian & mAbs Press Release Business Updates Microbial

Read press release

Prev 1 2

Our Company

Locations

Policies

Offerings

Services

Specialized Platforms & Programs

News & Blogs

Resources

Fact Sheet Quick Links

Join Us

What Drives Us

Meet Our Teams

Press Releases

Mammalian & mAbs (2)

AGC Biologics Copenhagen named Børsen Gazelle company for 2022

AGC Biologics Commercially Manufacture Provention Bio Diabetes Therapy

AGC Biologics and Gore Collaborate on New Protein A-based Purification Technology and Contract Manufacturing Services for Antibody Therapies

AGC Biologics Honored for Innovations in Cell Line Development

AGC Biologics Named Manufacturing Company of the Year by American Business Awards

Our Mission

Links

News

AGC Biologics’ Milan Site to Prepare Lentiviral Vector Commercial Manufacturing for Adaptimmune’s Lete-Cel Product

Events

NextGen Biomed, March 12-14